Literature DB >> 18220318

Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera.

Robert C Carlisle1, Reuben Benjamin, Simon S Briggs, Stephanie Sumner-Jones, Jenny McIntosh, Deborah Gill, Steve Hyde, Amit Nathwani, Vladimir Subr, Karel Ulbrich, Leonard W Seymour, Kerry D Fisher.   

Abstract

BACKGROUND: Copolymers based on poly-[N-(2-hydroxypropyl) methacrylamide] (HPMA) have been used previously to enable targeted delivery of adenovirus. Here we demonstrate polymer-coating techniques can also be used to modify and retarget adeno-associated virus (AAV) types 5 and 8.
METHODS: Three strategies for modifying transductional targeting of AAV were employed. The first involved direct reaction of AAV5 or AAV8 with amino-reactive HPMA copolymer. The second approach used carbodiimide (EDC) chemistry to increase the number of surface amino groups on the AAV5 capsid, thereby improving coating efficiency. In the third approach, the AAV5 genome was isolated from capsid proteins and delivered in a synthetic polyplex consisting of polyethylenimine (PEI) and HPMA.
RESULTS: Efficient covalent attachment of HPMA copolymer to AAV5 could only be achieved following modification of the virus with EDC. Coating inhibited sialic acid dependent infection and provided a platform for retargeting via new ligands, including basic fibroblast growth factor. Retargeted infection was shown to be partially resistant to neutralising antisera. Delivery of AAV5 genomes using PEI and HPMA was efficient and provided absolute control of tropism and protection from antisera. In contrast AAV8 could be reacted directly with HPMA copolymer and allowed specific retargeting via the epidermal growth factor receptor, but gave no protection against neutralising antisera.
CONCLUSIONS: Reactive HPMA polymers can be used to ablate the natural tropism of both AAV8 and EDC-modified AAV5 and enable receptor-specific infection by incorporation of targeting ligands. These data show transductional targeting strategies can be used to improve the versatility of AAV vectors. (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220318     DOI: 10.1002/jgm.1161

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  22 in total

Review 1.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

2.  Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.

Authors:  Chengwen Li; Nina Diprimio; Dawn E Bowles; Matthew L Hirsch; Paul E Monahan; Aravind Asokan; Joseph Rabinowitz; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 3.  Recombinant adeno-associated virus transduction and integration.

Authors:  Brian R Schultz; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

4.  Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees.

Authors:  K A Payne; H H Lee; A M Haleem; C Martins; Z Yuan; C Qiao; X Xiao; C R Chu
Journal:  Osteoarthritis Cartilage       Date:  2011-04-28       Impact factor: 6.576

5.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

Review 6.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 7.  Modified natural nanoparticles as contrast agents for medical imaging.

Authors:  David P Cormode; Peter A Jarzyna; Willem J M Mulder; Zahi A Fayad
Journal:  Adv Drug Deliv Rev       Date:  2009-11-06       Impact factor: 15.470

8.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Authors:  Michael J Castle; Heikki T Turunen; Luk H Vandenberghe; John H Wolfe
Journal:  Methods Mol Biol       Date:  2016

Review 9.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Authors:  Vedell Louis Jeune; Jakob A Joergensen; Roger J Hajjar; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2013-04-03       Impact factor: 2.396

10.  Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

Authors:  Robert C Carlisle; Ying Di; Anna M Cerny; Andreas F-P Sonnen; Robert B Sim; Nicola K Green; Vladimir Subr; Karel Ulbrich; Robert J C Gilbert; Kerry D Fisher; Robert W Finberg; Leonard W Seymour
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.